Continuous infusions of meropenem in ambulatory care: Clinical efficacy, safety and stability

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Manning, Laurens ^a,b   Wright, Cameron ^b   Ingram, Paul R ^c,d   Whitmore, Timothy J ^c   Heath, Christopher H ^a,c   Manson, Ingrid ^b   Page Sharp, Madhu ^e   Salman, Sam ^a   Dyer, John ^b   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Fremantle Hospital and Health Service   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOGLYCOSIDE; FOLIC ACID ANTAGONIST; MEROPENEM; QUINOLONE DERIVATIVE; VORICONAZOLE; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBULATORY CARE; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BURKHOLDERIA PSEUDOMALLEI; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STABILITY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; FEMALE; GRAM NEGATIVE BACTERIUM; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUTROPENIA; NOCARDIA; NONHUMAN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; ROOM TEMPERATURE; THROMBOCYTOPENIA; TREATMENT DURATION; ADVERSE EFFECTS; AUSTRALIA; CHEMISTRY; DOSE RESPONSE; EVALUATION STUDY; INFUSION; INFUSION PUMP; PROCEDURES; STANDARDS; TEMPERATURE;

AMBULATORY CARE; ANTI-INFECTIVE AGENTS; AUSTRALIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSION PUMPS; INFUSIONS, PARENTERAL; RETROSPECTIVE STUDIES; TEMPERATURE; THIENAMYCINS;

EID: 84904252176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102023     Document Type: Article

References (21)

1. Bardin C, Astier A, Vulto A, Sewell G, Vigneron J, et al. (2011) Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr 69: 221-231.
2. Nicolau DP (2008) Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 47 Suppl 1: S32-40.
3. Jaruratanasirikul S, Sriwiriyajan S (2003) Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health 34: 627-629. (Pubitemid 38068080)
4. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM (2010) Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 65: 1073-1075.
5. Patel PR, Cook SE (1997) Stability of meropenem in intravenous solutions. Am J Health Syst Pharm 54: 412-421. (Pubitemid 27089727)
6. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM (2002) Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 46: 2327-2332. (Pubitemid 34793431)
7. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP (2004) Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 26: 493-501. (Pubitemid 38586450)
8. Smith DL, Bauer SM, Nicolau DP (2004) Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device. American Journal of Health-System Pharmacy 61: 1682-1685. (Pubitemid 39481378)
9. Franceschi L, Cojutti P, Baraldo M, Pea F (2014) Stability of Generic Meropenem Solutions for Administration by Continuous Infusion at Normal and Elevated Temperatures. Therapeutic Drug Monitoring.
10. Esposito S, Noviello S, Leone S, Tice A, Seibold G, et al. (2004) Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents 24: 473-478. (Pubitemid 39425160)
11. Bureau of Meteorology (2013) Climate statistics for Australian locations.
12. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, et al. (2008) Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. Journal of Antimicrobial Chemotherapy 62: 168-171. (Pubitemid 351865892)
13. Food and Drug Administration (2009) Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation In: Research CfDEa, editor. Silver Spring, MD.
14. Li C, Kuti JL, Nightingale CH, Nicolau DP (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46: 1171-1178. (Pubitemid 44387417)
15. CLSI (2012) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute.
16. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, et al. (2004) Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 38: 1651-1672. (Pubitemid 38781656)
17. Norton K, Ingram PR, Heath CH, Manning L (2013) Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital. J Antimicrob Chemother in press.
18. Norton K, Ingram PR, Heath CH, Manning L (2013) Neutropenia is rare in patients receiving continuous infusions of vancomycin in an Australian Hospital in the Home setting. Intern Med J 43: 954-955.
19. Peralta FG, Sanchez MB, Roiz MP, Pena MA, Tejero MA, et al. (2003) Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Clinical Infectious Diseases 37: 1568-1572. (Pubitemid 37494687)
20. Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS (2011) Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. P T 36: 723-763.
21. Mendez A, Chagastelles P, Palma E, Nardi N, Schapoval E (2008) Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. Int J Pharm 350: 95-102. (Pubitemid 351146678)